Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia ...

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular researchPresentations ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting being held in ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...

Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...